Marinus Pharmaceuticals Inc logo

MRNS

Marinus Pharmaceuticals Inc

$6.5

Earnings Summary

Revenue
$14.19Mn
Net Profits
$-19.36Mn
Net Profit Margins
-136.48%

Highlights

Revenue:

Marinus Pharmaceuticals Inc’s revenue jumped 685.49% since last year same period to $14.19Mn in the Q1 2022. On a quarterly growth basis, Marinus Pharmaceuticals Inc has generated 265.07% jump in its revenue since last 3-months.

Net Profits:

Marinus Pharmaceuticals Inc’s net profit jumped 28.67% since last year same period to $-19.36Mn in the Q1 2022. On a quarterly growth basis, Marinus Pharmaceuticals Inc has generated 31.6% jump in its net profits since last 3-months.

Net Profit Margins:

Marinus Pharmaceuticals Inc’s net profit margin jumped 90.92% since last year same period to -136.48% in the Q1 2022. On a quarterly growth basis, Marinus Pharmaceuticals Inc has generated -141.44% fall in its net profit margins since last 3-months.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the Marinus Pharmaceuticals Inc post its latest quarter earnings

EPS Estimate Current Quarter
-0.68
EPS Estimate Current Year
-0.68

Highlights

EPS Estimate Current Quarter:

Marinus Pharmaceuticals Inc’s earning per share (EPS) estimates for the current quarter stand at -0.68 - a 20% jump from last quarter’s estimates.

EPS Estimate Current Year:

Marinus Pharmaceuticals Inc’s earning per share (EPS) estimates for the current year stand at -0.68.

Key Ratios

Key ratios of the Marinus Pharmaceuticals Inc post its Q1 2022 earnings

Earning Per Share (EPS)
-0.52
Return on Assets (ROA)
-0.51
Return on Equity (ROE)
-2.14
Dividend Per Share (DPS)
0

Highlights

Earning Per Share (EPS):

Marinus Pharmaceuticals Inc’s earning per share (EPS) jumped 29.73% since last year same period to -0.52 in the Q1 2022. This indicates that the Marinus Pharmaceuticals Inc has generated 29.73% annual rate of jump in its earning per share (EPS) in the last 4 quarters.

Return on Assets (ROA):

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Marinus Pharmaceuticals Inc’s return on assets (ROA) stands at -0.51.

Earning Per Share (EPS):

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Marinus Pharmaceuticals Inc’s return on equity (ROE) stands at -2.14.

Dividend Per Share (DPS):

Marinus Pharmaceuticals Inc declared 0 dividend per share during the earnings announcement for Q1 2022.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %
2022-05-12
-0.85
-0.52
38.82%

Company Information

Marinus Pharmaceuticals, Inc. is a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders. Ganaxolone is a positive allosteric modulator of GABAA receptors that acts on a well-characterized target in the brain known to have anti-seizure, anti-depressant and anti-anxiety potential. Ganaxolone is being developed in IV and oral dose forms intended to maximize therapeutic reach to adult and pediatric patient populations in both acute and chronic care settings. Marinus recently completed the first ever Phase 3 pivotal trial in children with CDKL5 deficiency disorder and is conducting a Phase 3 trial in refractory status epilepticus, Phase 2 trial in tuberous sclerosis complex and a Phase 2 biomarker-driven proof-of-concept trial in PCDH19-related epilepsy.

Organisation
Marinus Pharmaceuticals Inc
Employees
69
Industry
Health Technology